Alimera Sciences Inc. (NASDAQ: ALIM)
$5.57
-0.0300 ( -0.54% ) 125.4K
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
Market Data
Open
$5.57
Previous close
$5.60
Volume
125.4K
Market cap
$291.28M
Day range
$5.53 - $5.63
52 week range
$2.61 - $5.65
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Jun 24, 2024 |
8-k | 8K-related | 18 | Jun 24, 2024 |
8-k | 8K-related | 16 | May 14, 2024 |
10-q | Quarterly Reports | 78 | May 14, 2024 |
10-k/a | Quarterly Reports | 15 | Apr 29, 2024 |
4 | Insider transactions | 1 | Apr 02, 2024 |
4 | Insider transactions | 1 | Mar 13, 2024 |
4 | Insider transactions | 1 | Mar 13, 2024 |
4 | Insider transactions | 1 | Mar 13, 2024 |
4 | Insider transactions | 1 | Mar 13, 2024 |